Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. on April 5, 2017. The filing discloses the appointment of a new senior executive officer. Note: The request metadata references "Decoy Therapeutics Inc.," but the filing text explicitly identifies the registrant as Flex Pharma, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the appointment of William McVicar, Ph.D., as President, Research and Development, effective April 5, 2017. Dr. McVicar previously held leadership roles at Inotek Pharmaceuticals Corporation, including Executive Vice President and Chief Scientific Officer.
Management Commentary and Compensation Details
Dr. McVicar entered into an Executive Employment Agreement with the following terms:
- Base Salary: $380,000 annually.
- Annual Bonus: Target of 40% of the annualized base salary, contingent on performance and company goals.
- Severance: Nine months of salary continuation if terminated without Cause or if he resigns for Good Reason.
- Equity Grant: Stock option to purchase 200,000 shares of Common Stock at the closing price on the grant date.
- Vesting Schedule: 25% vests on the first anniversary; the remaining 75% vests monthly over the subsequent three years.
- Change in Control: 100% acceleration of unvested equity awards if terminated without Cause or resigns for Good Reason within a specific window surrounding a Change in Control.
Investor Verification Checklist
- Verify the full text of the Executive Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the closing stock price on April 5, 2017, to calculate the exercise price of the 200,000 stock options.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Check subsequent filings for any updates to the company's financial status or R&D pipeline progress under new leadership.